Amgen (AMGN) Initiates Phase 3 Trial of Sotorasib Combination Therapy for First-line Treatment of Non-Small Cell Lung Cancer
Strategic Phase 3 Trial to Position as First-line Therapy
Amgen (Amgen, AMGN) is conducting a large-scale Phase 3 clinical trial (CodeBreaK 202, NCT05920356) to expand the indications of its KRAS G12C inhibitor, sotorasib (brand name Lumakras). This trial targets patients with previously untreated Stage IV or advanced (Stage IIIB/C) non-squamous non-small cell lung cancer (NSCLC) who are positive for KRAS G12C mutation and negative for PD-L1 expression. The key objective is to directly compare the efficacy of sotorasib in combination with platinum-based doublet chemotherapy (carboplatin and pemetrexed) against the standard regimen of pembrolizumab (brand name Keytruda), an immune checkpoint inhibitor, in combination with platinum-based chemotherapy.
Mechanistic Precision of Targeted and Immune Therapies
Sotorasib works by directly targeting the mutated KRAS G12C protein, which drives cancer cell growth, and inhibiting its active state. In contrast, pembrolizumab functions as an immune checkpoint inhibitor by binding to PD-1 receptors on immune cells to neutralize cancer cell immune evasion mechanisms. This trial specifically focuses on PD-L1-negative patients, who typically show lower response rates to immune checkpoint inhibitors. The biopharma industry is closely watching whether the sotorasib-based combination therapy can demonstrate superior progression-free survival (PFS) and overall survival (OS) compared to the current standard of care.
Precision Medicine Strategy for Patient Subgrouping and New Treatment Standards
The CodeBreaK 202 trial is specifically designed for patients with NSCLC who meet both KRAS G12C mutation and PD-L1-negative biomarker criteria. This approach reflects a high-precision medicine strategy aimed at maximizing treatment success rates in patients who may not benefit from existing immunotherapy regimens, rather than pursuing a broad first-line market entry. This subgrouping strategy can provide personalized treatment opportunities for patients and offer clear clinical evidence for physicians in areas with high unmet medical needs.
Commercial Implications of First-line Market Entry
Currently, sotorasib is primarily approved as a second-line therapy, which has limited its revenue growth potential. However, success in this trial could enable Amgen to enter the large first-line therapy market, significantly expanding its commercial footprint. The global KRAS G12C inhibitor market is estimated to be worth approximately $1.12 billion in 2024 and is projected to grow to around $5.32 billion by 2033. This head-to-head trial against pembrolizumab, a blockbuster drug with annual sales of approximately $31.7 billion in 2025, is expected to serve as a pivotal milestone for diversifying and strengthening Amgen’s oncology business revenue structure.
This Phase 3 trial (CodeBreaK 202) represents a mid-to-long-term strategic move for sotorasib to overcome market limitations and establish a first-line treatment hegemony in the KRAS G12C inhibitor market, which is estimated at $1.12 billion in 2024. By targeting the niche PD-L1-negative patient population and aiming to demonstrate superiority over pembrolizumab, which generated $31.7 billion in annual sales in 2025, this trial could become a key driver for diversifying Amgen’s oncology pipeline revenue. Particularly, it serves as a preemptive clinical defense strategy to widen the gap against latecomers such as Bristol Myers Squibb’s adagrasib (brand name Krazati). From a research and clinical perspective, this trial holds significant academic value by potentially offering a new first-line standard of care based on targeted therapy for patients with specific mutations who show poor response to immunotherapy monotherapy. Ultimately, the success or failure of this trial will determine whether the prescription pattern for KRAS-targeted therapies shifts entirely from second-line to first-line treatment, thereby accelerating long-term market expansion.
Source: ClinicalTrials.gov (api_ct)